IMPROVEMENT OF PRICE REGULATION FOR INNOVATIVE MEDICINES COVERED BY THE NATIONAL BUDGET
https://doi.org/10.17749/2070-4909.2017.10.4.025-030
Abstract
The current approaches to the drug pricing commonly used worldwide allow for incorporating the therapeutic value of the drug into its consumer price. The drug pricing system existing in the Russian Federation restricts the availability of highly effective innovative drugs and leads to unnecessary expenses of the national budget. In this article, we propose a novel concept of price control relevant to Russia, which is based on the approaches used elsewhere.
About the Authors
V. A. Lemeshko
M. Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation; Centre of Expertise and quality control of Russian Ministry of Health care
Russian Federation
Russian Federation
Lemeshko Valeriya Alexandrovna – Specialist, the Department of Methodological Support for Comprehensive Health Technology Assessment CHQAC MHRF; PhD student at the Department of Pharmacology, Faculty of Pharmacy FMMU n. a. Sechenov.
Khokhlovsky per., 10-5, Moscow, 109028; Ul. Trubetskaya, 8-2, Moscow, 119991
N. Z. Musina
M. Sechenov First Moscow State Medical University, Ministry of Healthcare of the Russian Federation; Centre of Expertise and quality control of Russian Ministry of Health care
Russian Federation
Russian Federation
Musina Nuriya Zagitovna – PhD in Pharmacology, Lecturer at the Department of Pharmacology, Faculty of Pharmacy FMMU n. a. Sechenov; Chief of the development and communications CHQAC MHRF; Senior researcher at the Health Care Finance CRFIMFRF.
Ul. Trubetskaya, 8-2, Moscow, 119991; 117335, Moscow, POB 90, tel.: +7 (499) 9569528; Khokhlovsky per., 10-5, Moscow, 109028
V. K. Fedyaeva
The Russian Presidential Academy of National Economy and Public Administration; Research Financial Institution of the Ministry of Finance of the Russian Federation, Federal State Budget Institution
Russian Federation
Russian Federation
Fedyaeva Vlada Konstantinovna – Researcher at the Center for Health Technology Assessment RPANEPA; Senior laboratory assistant at the Health Care Finance CRFIMFRF
117335, Moscow, POB 90, phone: +7 (499) 9569528
References
1. The pharmaceutical industry and global health: fact and figures 2017 [Byulleten’ mezhdunarodnoi Federatsii farmatsevticheskikh proizvoditelei i assotsiatsii (in Russian)]. URL: http://www.ifpma.org/wp-content/uploads/2017/02/IFPMA-Facts-And-Figures-2017.pdf. Data obrashcheniya: 05.03.2017.
2. Khonl T. A. Problemy ucheta i finansov (in Russian). 2013; 2 (10): 52-54. URL: http://cyberleninka.ru/article/n/zatraty-na-razrabotkuinnovatsionnogo-lekarstvennogo-preparata. Accessed: 05.03.2017.
3. Akhmetov A. E. Vestnik RUDN. Seriya Ekonomika (in Russian). 2012; 2: 39-45. URL: http://journals.rudn.ru/economics/article/viewFile/12009/11439. Accessed: 05.03.2017.
4. Yakunina A. V. Nauka i obshchestvo (in Russian). 2014; 3 (18): 19-26.
5. Bel’skikh I. E., Kulagina S. V. Mezhdunarodnyi bukhgalterskii uchet (in Russian). 2011; 14 (164): 38-45.
6. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. WHO 2015. URL: http://apps.who.int/medicinedocs/documents/s21793en/s21793en.pdf. Accessed: 05.03.2017.
7. WHO guideline on country pharmaceutical pricing policies. WHO 2015. URL: http://apps.who.int/medicinedocs/documents/s21016en/s21016en.pdf. Accessed: 05.03.2017.
8. Huttin C. Chapter 8: Experiences with reference pricing. Drugs Money – Prices Affordabil. Cost Contain. Part II Sel. Exp. Policy Options [Internet]. World Health Organization; 2003. URL: http://apps.who.int/medicinedocs/en/d/Js4912e/3.3.html#Js4912e.3.3. Accessed: 10.03.2017.
9. Access to medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research WorldHealth Organisation, March 2015 URL: http://apps.who.int/medicinedocs/documents/s21793en/s21793en.pdf. Accessed: 05.03.2017.
10. Omel’yanovskii V. V., Sura M. V., Sveshnikova N. D. Pediatricheskaya farmakologiya (in Russian). 2011; 4: 30-35.
11. Multi-Indication Pricing: Pros, Cons and Applicability to the UK. URL: https://www.slideshare.net/OHENews/multiindication-pricing-proscons-and-applicability-to-the-uk-64621749. Accessed: 05.03.2017.
12. Sussex J., Towse A., Devlin N. Operationalizing value-based pricing of medicines. Pharmacoeconomics. 2013; 31 (1): 1-10.
13. Dzhalalov S. Ch., Dzhalalova D. Kh., Khoch D. S. Meditsinskie tekhnologii. Otsenka i vybor (in Russian). 2013; 1 (11): 63-69.
14. Resolution of the Government of the Russian Federation on October 29, 2010 No. 865 “On state regulation of prices for LP, included in the list of vital and most important LPs” (ed. 03.02.2016) [Postanovlenie Pravitel’stva RF 29 oktyabrya 2010 g. № 865 «O gosudarstvennom regulirovanii tsen na LP, vklyuchennye v perechen’ zhiznenno neobkhodimykh i vazhneishikh LP» (red. ot 03.02.2016) (in Russian)].
15. Resolution of the Government of the Russian Federation of September 15, 2015 № 979 “On Amendments to the Resolution of the Government of the Russian Federation of October 29, 2010 No. 865 and on the approval of the calculation methodology set by the LP producers of the maximum selling prices for LPs included in the list of vital and essential LP, at their state registration and re-registration” [Postanovlenie Pravitel’stva RF ot 15.09.2015 № 979 «O vnesenii izmenenii v postanovlenie Pravitel’stva Rossiiskoi Federatsii ot 29 oktyabrya 2010 g. № 865 i ob utverzhdenii metodiki rascheta, ustanavlivaemykh proizvoditelyami LP predel’nykh otpusknykh tsen na LP, vklyuchennye v perechen’ zhiznenno neobkhodimykh i vazhneishikh LP, pri ikh gosudarstvennoi registratsii i pereregistratsii» (in Russian)].
16. Fedyaev D. V., Maksimova L. V., Omel’yanovskii V. V. Meditsinskie tekhnologii. Otsenka i vybor (in Russian). 2014; 1: 57-64.
Review
For citations:
Lemeshko V.A., Musina N.Z., Fedyaeva V.K. IMPROVEMENT OF PRICE REGULATION FOR INNOVATIVE MEDICINES COVERED BY THE NATIONAL BUDGET. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2017;10(4):25-30. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.4.025-030
Views:
966
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 